Cardiogenic Shock: A 55 year old with no known medical problems - - PDF document

cardiogenic shock
SMART_READER_LITE
LIVE PREVIEW

Cardiogenic Shock: A 55 year old with no known medical problems - - PDF document

12/17/16 Case Cardiogenic Shock: A 55 year old with no known medical problems presents with an anterior STEMI 5 days after the start of symptoms. Pharmacological and Despite prompt revascularization and vasopressor support hypotension


slide-1
SLIDE 1

12/17/16 1

Cardiogenic Shock: Pharmacological and Mechanical Therapy

Christopher Barnett MD, MPH Director, Medical Cardiovascular Intensive Care Unit Director, Pulmonary Hypertension Program Medstar Heart and Vascular Institute Medstar Washington Hospital Center Washington, DC

Case

  • A 55 year old with no known medical problems presents

with an anterior STEMI 5 days after the start of symptoms.

  • Despite prompt revascularization and vasopressor support

hypotension persists and

  • An IABP is inserted with temporary improvement in

hemodynamics.

  • An echocardiogram demonstrates a ventricular septal defect

and he is taken urgently to the operating room for repair.

  • Post operatively hemodynamics deteriorate and he is placed
  • n ECMO.
  • Seven days later he is weaned off ECMO and decanulated.
  • He is subsequently discharged home from the hospital.

Shock is Inadequate End Organ Perfusion Despite Adequate Fluid Resuscitation

  • Criteria for the diagnosis of cardiogenic shock
  • SBP <90 for >30 minutes or vasopressor needed to

maintain SBP >90

  • Pulmonary congestion/elevated LV filling pressures
  • Signs of impaired perfusion
  • Mental status
  • Cool extremities
  • Oliguria
  • Elevated lactate

Differential Diagnosis of Cardiogenic Shock in Patients in the CVICU

  • Complications of acute myocardial infarction
  • Left ventricular dysfunction (80% of cardiogenic shock)
  • VSD
  • Ventricular wall rupture
  • Acute valvular heart disease
  • Decompensated chronic HFrEF
  • HFpEF
  • Viral cardiomyopathy
  • Post cardiotomy
  • Arrhythmia
  • Valvular heart disease
  • Right ventricular failure
  • Post operative right ventricular failure
  • Decompensated chronic pulmonary hypertension
slide-2
SLIDE 2

12/17/16 2

Don’t Forget About Non- Cardiogenic Causes of Shock!

  • Distributive
  • Sepsis
  • Obstructive
  • Pulmonary embolism
  • Neurogenic
  • Spinal chord injury
  • Hypovolemic
  • Acute blood loss
  • Intravascular volume depletion

Mortality in Cardiogenic Shock Is High

  • Secondary to acute MI

22-88%

  • Ventricular septal

rupture 87%

  • Right ventricular failure

from PAH 30-48% Factors associated with increased mortality after acute MI:

  • Advanced age
  • Shock on admission
  • Clinical end organ hypoperfusion
  • Anoxic brain injury
  • Decreasing SBP
  • Prior CABG
  • Non-inferior AMI
  • Creatinine >1.9
  • Machuca. Circulation, 2015.
  • Reyentovich. Nat Reviews Cardiology, 2016.

Initial Cardiac Dysfunction Leads To A Cascade of Downstream Abnormalities

  • Reyentovich. Nat CV Reviews, 2016.

Approach to Patients With Suspected Cardiogenic Shock

  • Optimize volume status
  • Use vasopressors to maintain adequate blood pressure

to prevent end organ ischemia and dysfunction

  • Use Inotropes (inodilators) to optimize cardiac output
  • Continually reevaluate response to therapy
  • Consider surgical repair of structural heart disease early
  • Consider implementation of mechanical support early
slide-3
SLIDE 3

12/17/16 3

Survival Is Improved With Early Revascularization in SHOCK From ACS

  • Hochman. JAMA, 2006.
  • Hochman. NEJM, 1999.

It Is Unknown If Culprit PCI Is Superior to Multivessel PCI In Shock

http://www.culprit-shock.eu/the-project/

The Pulmonary Artery Catheter Is Useful Carefully Selected Patients With Cardiogenic Shock

  • Escape trial
  • Found not difference in
  • utcomes between

therapy guided with PAC

  • r without
  • Excluded Dobutamine
  • r dopamine >3

mcg/kg/min, any milrinone, Cr>3.5

  • Binanay. JAMA, 2005.
  • Chaterjee. Circulation, 2009.

Alpha Agonists: Mechanism of Action

  • Overgaard. Circulation, 2008.
slide-4
SLIDE 4

12/17/16 4 Mechanism of Action: Beta Agonists

  • Overgaard. Circulation, 2008.

Vascular smooth muscle Cardiac myocyte

Mechanism of PDE- Inhibitor: Milrinone

  • Overgaard. Circulation, 2008.

Catecholaminergic Receptor Activity

Drug α β1 β2 D Dopamine +++ (3+) ++++ (4+) ++ (2+) +++++ (5+) Dobutamine + (1+) +++++ (5+) +++ (3+) NA Norepinepherine +++++ (5+) +++ (3+) ++ (2+) NA Epinepherine +++++ (5+) ++++ (4+) +++ (3+) NA Isoproterenol +++++ (5+) +++++ (5+) NA Phenylepherine +++++ (5+) NA

  • Overgaard. Circulation, 2008.

Vasopressors In Cardiogenic Shock: What Choice Is Best?

  • Shock trial: Increased

death with dopamine in cardiogenic shock

  • Post hoc subset

analysis of 280 patients

  • Pressor choice requires

careful consideration of individual patient hemodynamics to choose the optimal vasopressor

De Backer. NEJM, 2010. . Death at 28 days

slide-5
SLIDE 5

12/17/16 5

Mechanisms and Hemodynamic Effects of IABP

  • Increased diastolic

blood flow to the proximal aorta

  • Reduced afterload due

to vacuum effect of balloon deflation

  • ↓SBP
  • ↑ DBP
  • ↑ MAP
  • ↓ HR
  • ↓ PCWP
  • ↑ CO
  • ↑ Coronary perfusion

Hemodynamic Benefits From IABP Varies By Population Studied

  • Prodzinsky. Shock, 2012.

Hemodynamic Benefits From IABP Varies By Population Studied

  • Stone. JACC, 2003.

Routine Use Of An IABP After AMI Does Not Improve Outcomes

  • 598 patients with

hypotension pulmonary edema and impaired end organ perfusion

  • No difference in

mortality

  • Trend towards benefit

in younger patients without prior MI and anterior MI

  • Theile. NEJM, 2012.
slide-6
SLIDE 6

12/17/16 6

O’Gara. JACC, 2013.

Current Percutaneous Mechanical Support Options

  • Theile. Eur Heart J, 2015.

Characteristics of Temporary Mechanical Support Devices

  • Reyentovich. Nat Reviews Cardiology, 2016.

Patient Factors To Be Considered In Mechanical Support

  • Irreversible neurological damage
  • Intracranial bleeding or other condition that

precludes anticoagulation

  • Inaccessible vessels for cannulation
  • Irreversible cardiopulmonary failure in patients

who are no candidates for transplantation

  • Multiorgan dysfunction
  • Malignant disease with <5 year life expectancy
  • Potential for rehabilitation and quality of life after

recovery

  • Machuca. Circulation, 2015.
slide-7
SLIDE 7

12/17/16 7

Impella Device

Impella Registry: Early Implantation

  • f Impella May Improve Outcomes

O’Neill. J Int Cardiology, 2014.

Impella Registry: Early Implantation

  • f Impella May Improve Outcomes

O’Neill. J Int Cardiology, 2014.

slide-8
SLIDE 8

12/17/16 8

IMPRESS trial of Impella Compared to IABP In Cardiogenic Shock: No Difference In Mortality

  • Ouweneel. JACC. 2016.

Meta Analysis Demonstrates Better Hemodynamics, Increased Complications, Similar Outcomes

  • Cheng. Eur Heart J, 2009.

Meta Analysis Demonstrates Better Hemodynamics, Increased Complications, Similar Outcomes

  • Cheng. Eur Heart J, 2009.
slide-9
SLIDE 9

12/17/16 9

Few Data To Evaluate ECMO

  • Machuca. Circulation, 2015.

The Use Of MCS Devices Has Increased Dramatically

  • Stretch. JACC, 2014.

Mortality Has Decreased For Recipients

  • f Short Term Mechanical Support
  • Stretch. JACC, 2014.

Shift To Earlier Use of Percutaneous Devices for MCS

  • Stretch. JACC, 2014.
slide-10
SLIDE 10

12/17/16 10

A Team Approach To Evaluation Of The Candidates For Advanced Mechanical Support Is Recommended

  • Heart failure/heart transplant specialist
  • Intensivist
  • Cardiac surgeon

Pathway to Decision for Use of MCS

Peura Circulation, 2012.

Considerations In Choosing Mechanical Support

  • Thiele. Eur Heart J., 2015.